Alerts will be sent to your verified email
Verify Email
SHILPAMED
|
Shilpa Medicare
|
Acutaas Chemicals
|
Aarti Pharmalabs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
30.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
16.0 . | n/a | n/a |
|
Number of ANDA's Filed in Europe
|
81.0 | n/a | n/a |
|
US DMF Filings
|
45.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
2.69 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
5.0 % | 18.21 % | 7.89 % |
|
5yr average Equity Multiplier
|
1.64 | 1.75 | 1.37 |
|
5yr Average Asset Turnover Ratio
|
0.39 | 0.82 | 0.54 |
|
5yr Avg Net Profit Margin
|
7.72 % | 12.12 % | 7.96 % |
|
Price to Book
|
3.55 | 7.14 | 3.91 |
|
P/E
|
107.57 | 58.88 | 28.59 |
|
5yr Avg Cash Conversion Cycle
|
76.54 Days | 58.6 Days | 89.79 Days |
|
Inventory Days
|
105.79 Days | 65.78 Days | 92.09 Days |
|
Days Receivable
|
113.53 Days | 111.06 Days | 95.5 Days |
|
Days Payable
|
120.58 Days | 142.05 Days | 69.05 Days |
|
5yr Average Interest Coverage Ratio
|
11.52 | 19.71 | 11.46 |
|
5yr Avg ROCE
|
6.65 % | 22.58 % | 10.86 % |
|
5yr Avg Operating Profit Margin
|
17.76 % | 19.73 % | 13.88 % |
|
5 yr average Debt to Equity
|
0.44 | 0.34 | 0.15 |
|
5yr CAGR Net Profit
|
-27.23 % | 9.26 % | n/a |
|
5yr Average Return on Assets
|
3.1 % | 10.12 % | 5.29 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
44.23 % | 35.96 % | 44.29 % |
|
Share Pledged by Promoters
|
7.92 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-5.78 % | -5.09 % | -1.69 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
3.04 % | 10.94 % | -4.33 % |
|
Shilpa Medicare
|
Acutaas Chemicals
|
Aarti Pharmalabs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|